Market Dynamics: Banking vs. Pharma

This chapter examines the changing market landscape, focusing on J.P. Morgan's rise toward a trillion-dollar market cap and the challenges faced by Eli Lilly. It highlights the growth in the banking sector amidst rising earnings estimates and explores the implications of Federal Reserve policies on both drug and bank stocks.